Cerebrospinal fluid D-serine and glycine concentrations are unaltered and unaffected by olanzapine therapy in male schizophrenic patients

Sabine A Fuchs, Martina M J De Barse, Floor E Scheepers, Wiepke Cahn, Lambertus Dorland, Monique G de Sain-van der Velden, Leo W J Klomp, Ruud Berger, René S Kahn, Tom J de Koning

Research output: Contribution to journalArticleAcademicpeer-review

25 Citations (Scopus)


N-Methyl D-aspartate (NMDA)-receptor hypofunction has been implicated in the pathophysiology of schizophrenia and D-serine and glycine add-on therapy to antipsychotics has shown beneficial effects in schizophrenic patients. Nevertheless, previous studies have not shown consistently altered D-serine concentrations in cerebrospinal fluid (CSF) of schizophrenic patients. To confirm and extend these results, CSF concentrations of both endogenous NMDA-receptor co-agonists d-serine and glycine and their common precursor L-serine were analyzed simultaneously in 17 healthy controls and 19 schizophrenic patients before and 6 weeks after daily olanzapine (10 mg) treatment. CSF D-serine, L-serine and glycine concentrations and their relative ratios were similar between schizophrenic patients and controls and no differences were observed before and after olanzapine therapy. Thus, the NMDA-receptor hypofunction hypothesis in schizophrenia is not explained by olanzapine therapy-dependent absolute or relative decreases in CSF D-serine and glycine concentrations in this series of male patients, thereby not providing convenient markers for the disorder.

Original languageEnglish
Pages (from-to)333-338
Number of pages6
JournalEuropean Neuropsychopharmacology
Issue number5
Publication statusPublished - May-2008
Externally publishedYes


  • Adult
  • Antipsychotic Agents
  • Benzodiazepines
  • Glycine
  • Humans
  • Male
  • Middle Aged
  • Schizophrenia
  • Serine
  • Clinical Trial
  • Journal Article
  • Research Support, Non-U.S. Gov't

Cite this